| |
Twice Daily Telaprevir in Combination With Peginterferon Alfa-2a/Ribavirin in HCV Genotype 1 Liver Transplant Recipients: Interim Pharmacokinetics of the REFRESH Study
|
| |
| |
Reported by Jules Levin
Presented at the American Transplant Congress, May 18Ð22, 2013, in Seattle, Washington
Hugo E. Vargas, MD1; Yang Dai, PhD2; Kimberly A. Brown, MD3; Mark W. Russo, MD4; Eric Yoshida, MD5; Robert J. Fontana, MD6; Josh Levitsky, MD7;
Raymond Rubin, MD2; Varun Garg, PhD2; Robert S. Brown, MD, MPH8
1Mayo Clinic, Scottsdale, AZ, USA; 2Vertex Pharmaceuticals Incorporated, Cambridge, MA, USA; 3Henry Ford Hospital, Detroit, MI, USA; 4Carolinas Medical Center, Charlotte, NC, USA; 5University of British Columbia, Vancouver, British Columbia, CAN; 6University of Michigan, Ann Arbor, MI, USA; 7Northwestern University, Chicago, IL, USA; 8Columbia University, New York, NY, USA
|
|
| |
| |
|
|
|
